Webinar on RWE in Drug Development and FDA Guidelines, RWE Used in 75% of FDA Approvals Last Year

A new webinar features insight from key leaders at Aetion, Sanofi, and Janssen. They discuss the impacts of RWE (real world evidence) on the regulatory decision-making landscape. In 2019, RWE was only used in 49% of studies leading to FDA approval for biologics and prescription drugs, but rose to 75% last year. Understanding and effectively using RWE will continue to be important in 2021 at all stages of drug development.

“In this webinar, hear from global biopharma leaders and Aetion about the state of RWE, including learnings from collaborations with regulators and perspectives from biopharma organizations who are leading comprehensive approaches to integrating RWE across the drug lifecycle.” Learn more here.

(Source: Pink Sheet, Informa Pharma Intelligence, 2021)